Strong UCB 1Q revenues hide weaker Cimzia performance
This article was originally published in Scrip
Executive Summary
Belgium's UCB reported strong revenue growth of 19% (11% at constant currencies) in the first quarter beating consensus, but one-off stocking of the epilepsy drug Keppra in the US hid a disappointing performance of its anti-inflammatory Cimzia in that market.